Cited by 219Hepatitis B Virus StudiesHepatitis C virus researchLiver physiology and pathology

The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.

Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy

Open access

Sung, Joseph J.Y., Wong, May-Ling, Bowden, Scott, Liew, Choong-Tsek, Hui, Alex Y., Wong, Vincent W.S., Leung, Nancy W.Y., Locarnini, Stephen, Chan, Henry L.Y.·2005·Gastroenterology

DOI 10.1053/j.gastro.2005.03.009

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims This study aimed to determine whether intrahepatic hepatitis B virus (HBV) covalently closed circular (ccc) DNA and total HBV DNA levels at the end of therapy would predict sustained response to therapy.Methods Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B patients receiving either lamivudine monotherapy or combination of peginterferon and lamivudine had liver biopsy at the end of 1 year therapy and were followed for 52 more weeks after cessation of therapy. Serum HBV DNA, intrahepatic HBV ccc DNA, and total HBV DNA levels were determined.Results Forty-seven patients, including 34 males and 13 females, were studied. Twenty-seven patients received combination therapy, and 20 patients received lamivudine monotherapy. Twenty-nine patients had end-of-treatment virologic response, and 15 patients had sustained response 52 weeks after therapy. At the end of treatment, log serum HBV DNA levels correlated well with log intrahepatic HBV cccDNA and log intrahepatic total HBV DNA levels. Log intrahepatic cccDNA and log intrahepatic total DNA levels were significantly lower among patients with sustained virologic response. The adjusted odds ratio for log cccDNA was 5.3 (95% CI: 1.5-18.2, P = .009) and, for log intrahepatic HBV DNA, was 4.4 (95% CI: 1.3-14.7, P = .015) to predict sustained virologic response. Using log cccDNA at -0.80 copies/genome equivalent as cutoff, the sensitivity, specificity, and positive and negative predictive values and accuracy of predicting sustained virologic response were 73%, 78%, 56%, 86%, and 77% respectively.Conclusions Intrahepatic HBV cccDNA and intrahepatic total HBV DNA levels at the end of therapy are superior to serum HBV DNA as surrogates of sustained virologic response.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2005.03.009

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Chronic hepatitis B
Lok, A. S.-F., & McMahon, B. J. (2007) · Hepatology · doi:10.1002/hep.21513 · Cited by 3,092
Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆
Werle–Lapostolle, B., Bowden, S., Locarnini, S., Wursthorn, K., Petersen, J., Lau, G., Trepo, C., Marcellin, P., Goodman, Z., & Delaney IV, W. E. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.018 · Cited by 905
Chronic hepatitis B
Lok, A. S. F., & McMahon, B. J. (2001) · Hepatology · doi:10.1053/jhep.2001.29401 · Cited by 711
Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B
Liaw, Y., Leung, N. W. Y., Chang, T., Guan, R., Tai, D., Ng, K., Chien, R., Dent, J. C., Roman, L., Edmundson, S., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.8559 · Cited by 687
Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells
Tuttleman, J. S., Pourcel, C., & Summers, J. W. (1986) · Cell · doi:10.1016/0092-8674(86)90602-1 · Cited by 672
Prevalence and Clinical Correlates of YMDD Variants during Lamivudine Therapy for Patients with Chronic Hepatitis B
Lai, C., Dienstag, J. L., Schiff, E. R., Leung, N. W. Y., Atkins, M., Hunt, C. M., Brown, N. A., Woessner, M. A., Boehme, R. E., & Condreay, L. D. (2003) · Clinical Infectious Diseases · doi:10.1086/368083 · Cited by 633
Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase
Angus, P., Vaughan, R., Xiong, S., Yang, H., Delaney, W. E., Gibbs, C. S., Brosgart, C. L., Colledge, D., Edwards, R., Ayres, A., et al. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00939-9 · Cited by 563
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
Stuyver, L. J. (2001) · Hepatology · doi:10.1053/jhep.2001.22166 · Cited by 384
Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea
Song, B.-C., Suh, D. J., Lee, H. C., Chung, Y., & Lee, Y. S. (2000) · Hepatology · doi:10.1053/jhep.2000.16665 · Cited by 335
The covalently closed duplex form of the hepadnavirus genome exists in situ as a heterogeneous population of viral minichromosomes
Newbold, J. E., Xin, H., Tencza, M. G., Sherman, G., Dean, J., Bowden, S., & LOCARNINI, S. A. (1995) · Journal of Virology · doi:10.1128/jvi.69.6.3350-3357.1995 · Cited by 313

Show all 32 references

Sorted by citations

Items 101–200 of 219

HBV Reactivation in Patients Undergoing Hematopoietic Stem Cell Transplantation: A Narrative Review
Gentile, G., & Antonelli, G. (2019) · Viruses · doi:10.3390/v11111049 · Cited by 33
Antiviral activity of methyl helicterate isolated from Helicteres angustifolia (Sterculiaceae) against hepatitis B virus
Huang, Q., Huang, R., Wei, L., Chen, Y., Lv, S., Liang, C., Zhang, X., Yin, F., Li, H.-T., Zhuo, L., et al. (2013) · Antiviral Research · doi:10.1016/j.antiviral.2013.09.007 · Cited by 32
Treatment of Hepatitis B Virus: An Update
Ward, H., Tang, L., Poonia, B., & Kottilil, S. (2016) · Future Microbiology · doi:10.2217/fmb-2016-0128 · Cited by 33
Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B.
Chan, H. L., Wong, V. W., Chim, A. M., Choi, P. C., Chan, H., Hui, A., Wong, G. L., & Sung, J. J. �. (2007) · PubMed · Cited by 30
Virological Response to Different Combination Regimes of Peginterferon α-2b and Lamivudine in Hepatitis B e Antigen Positive Chronic Hepatitis B
Chan, H. L., Wong, V. W., Chim, A. M., Choi, P. C., Chan, H., Hui, A., Wong, G. L., & Sung, J. J. �. (2007) · Antiviral Therapy · doi:10.1177/135965350701200507 · Cited by 30
Enhanced specificity of real-time PCR for measurement of hepatitis B virus cccDNA using restriction endonuclease and plasmid-safe ATP-dependent DNase and selective primers
Gao, Y., Han, T., Li, Y., Yang, B., Wang, Y., Wang, F., Jing, X., & Zhi, D. (2010) · Journal of Virological Methods · doi:10.1016/j.jviromet.2010.07.031 · Cited by 28
Safety and Tolerability of Sequential Pegylated IFN-α2a and Tenofovir for Hepatitis B Infection in HIV+ Individuals
Johnson, R. M., Ristig, M. B., Overton, E. T., Lisker‐Melman, M., Cummings, O. W., & Aberg, J. A. (2007) · HIV Clinical Trials · doi:10.1310/hct0803-173 · Cited by 26
Early Hepatitis B Virus DNA Suppression Can Predict Virologic Response to Peginterferon and Lamivudine Treatment
Chan, H. L., Wong, V. W., Wong, G. L., Chim, A. M., Chan, H., & Sung, J. J. �. (2008) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2008.03.026 · Cited by 25
Hepatitis B Virology for Clinicians
Doo, E. C., & Ghany, M. G. (2010) · Clinics in Liver Disease · doi:10.1016/j.cld.2010.05.001 · Cited by 25
Serum hepatitis B surface antigen levels correlate with high serum HBV DNA levels in patients with chronic hepatitis B: A cross-sectional study
Gupta, E., Kumar, A., Choudhary, A., Kumar, M., & Sarin, S. (2012) · Indian Journal of Medical Microbiology · doi:10.4103/0255-0857.96664 · Cited by 25
Factors associated with the effect of interferon‐α sequential therapy in order to discontinue nucleoside/nucleotide analog treatment in patients with chronic hepatitis B
Matsumoto, A., Yatsuhashi, H., Nagaoka, S., Suzuki, Y., Hosaka, T., Tsuge, M., Chayama, K., Kanda, T., Yokosuka, O., Nishiguchi, S., et al. (2015) · Hepatology Research · doi:10.1111/hepr.12488 · Cited by 25
Analysis of intrahepatic total HBV DNA, cccDNA and serum HBsAg level in Chronic Hepatitis B patients with undetectable serum HBV DNA during oral antiviral therapy
Li, J., Sun, X., Fang, J., Wang, C., Han, G., & Ren, W. (2017) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2017.03.004 · Cited by 25
Relapse of chronic hepatitis B after discontinuation of nucleos(t)ide analogs: Is the glass half full or half empty?
Reijnders, J. G. P., & Janssen, H. L. A. (2013) · Hepatology · doi:10.1002/hep.26708 · Cited by 25
Serum HBV DNA plus RNA reflecting cccDNA level before and during NAs treatment in HBeAg positive CHB patients
Wang, Y., Liu, Y., Liao, H., Deng, Z., Bian, D., Ren, Y., Yu, G., Jiang, Y., Bai, L., Liu, S., et al. (2022) · International Journal of Medical Sciences · doi:10.7150/ijms.71737 · Cited by 24
Quantification of hepatitis B surface antigen with the novel DiaSorin LIAISON XL Murex HBsAg Quant: Correlation with the ARCHITECT quantitative assays
Burdino, E., Ruggiero, T., Proietti, A., Milia, M. G., Olivero, A., Caviglia, G. P., Marietti, M., Rizzetto, M., Smedile, A., & Ghisetti, V. (2014) · Journal of Clinical Virology · doi:10.1016/j.jcv.2014.05.013 · Cited by 24
REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY
Lynch, J. P., Metz, D. C., Schuppan, D., Junker, Y., & Barisani, D. (2009) · Cited by 24
Baseline value of intrahepatic HBV DNA over cccDNA predicts patient’s response to interferon therapy
Mu, D., Yuan, F., Chen, Y., Jiang, X.-Y., Yan, L., Jiang, L.-Y., Gong, J., Zhang, D., Ren, H., & Liao, Y. (2017) · Scientific Reports · doi:10.1038/s41598-017-05242-y · Cited by 24
Hepatitus B virus reactivation in HBV-DNA negative and positive patients with hematological malignancies
Yağcı, M., Özkurt, Z. N., Yeğin, Z. A., Akı, Ş. Z., Sucak, G. T., & Haznedar, R. (2010) · Hematology · doi:10.1179/102453309x12583347114059 · Cited by 23
Future prospectives for the management of chronic hepatitis B
Leemans, W. F. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i18.2554 · Cited by 23
Molecular methods in the diagnosis and management of chronic hepatitis B
Vivekanandan, P., & Singh, O. V. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.75 · Cited by 22
Impact of peginterferon alpha‐2b and entecavir hydrate combination therapy on persistent viral suppression in patients with chronic hepatitis B
Hagiwara, S., Kudo, M., Osaki, Y., Matsuo, H., Inuzuka, T., Matsumoto, A., Tanaka, E., Sakurai, T., Ueshima, K., Inoue, T., et al. (2013) · Journal of Medical Virology · doi:10.1002/jmv.23564 · Cited by 21
Relationship between HBV cccDNA expression in the human ovary and vertical transmission of HBV
Yu, M., Gu, X., Xia, Y., Wang, G. J., Kan, N.-Y., Jiang, H., Wu, K., Ji, Y., & JU, L. L. (2011) · Epidemiology and Infection · doi:10.1017/s0950268811002068 · Cited by 21
Impact of Intrahepatic Hepatitis B DNA and Covalently Closed Circular DNA on Survival After Hepatectomy in HBV-Associated Hepatocellular Carcinoma Patients
Wang, Q., Fiel, M. I., Luan, W., Blank, S., Kadri, H., Kim, K. W., & Hiotis, S. P. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-013-3046-y · Cited by 20
Combinational use of hepatitis B viral antigens predicts responses to nucleos(t)ide analogue/peg-interferon sequential therapy
Matsumoto, A., Nishiguchi, S., Enomoto, H., Kang, J., Tanaka, Y., Shinkai, N., Kurosaki, M., Enomoto, M., Kanda, T., Yokosuka, O., et al. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1360-z · Cited by 20
New insights into hepatitis B virus biology and implications for novel antiviral strategies
Chen, J., Wu, M., Liu, K., Zhang, W., Li, Y., Zhou, X., Bai, L., & Yuan, Z. (2015) · National Science Review · doi:10.1093/nsr/nwv044 · Cited by 20
Detection of hepatitis B virus covalently closed circular DNA in paraffin-embedded and cryo-preserved liver biopsies of chronic hepatitis B patients
Takkenberg, R. B., Zaaijer, H. L., Menting, S., Weegink, C. J., Terpstra, V., Cornelissen, M. T. E., Dijkgraaf, M. G. W., Jansen, P. L. M., Reesink, H. W., & Beld, M. (2010) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0b013e3283376a63 · Cited by 18
The Natural History and the Staging of Chronic Hepatitis B: Time for Reevaluation of the Virus–Host Relationship Based on Molecular Virology and Immunopathogenesis Considerations?
Thompson, A. J. V., LOCARNINI, S. A., & Visvanathan, K. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.07.038 · Cited by 18
New developments in antiviral therapy for chronic hepatitis B
Takkenberg, R. B., Weegink, C. J., Zaaijer, H. L., & Reesink, H. W. (2009) · Vox Sanguinis · doi:10.1111/j.1423-0410.2009.01282.x · Cited by 18
Prevention and risk factors of hepatitis B recurrence after living donor liver transplantation
Na, G. H., Kim, D. G., Han, J. H., Kim, E. Y., Lee, S. H., Hong, T. H., You, Y. K., & Choi, J. Y. (2013) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.12403 · Cited by 17
Quantification of intrahepatic total hepatitis B virus DNA in chronic hepatitis B patients and its relationship with liver histology
Bayram, A., Erkiliç, S., Özkur, A., Bayram, M., & Sarı, İ. (2007) · Journal of Clinical Pathology · doi:10.1136/jcp.2007.050765 · Cited by 17
The role of hepatitis B core‐related antigen in predicting hepatitis B virus recurrence after liver transplantation
Yu, J., Ye, Y., Liu, J., Xu, Y., Lou, B., Zhu, J., Sheng, X., Feng, X., Pan, Q., Yang, J., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15429 · Cited by 17
Scientific and Medical Evidence Informing Expansion of HBV Treatment Guidelines
Kennedy, P., Allweiss, L., Bertoletti, A., Cornberg, M., Gehring, A., Guidotti, L. G., Kerth, H., Lemoine, M., Levrero, M., Lim, S. G., et al. (2025) · The Lancet Gastroenterology and Hepatology · doi:10.1016/s2468-1253(25)00053-6 · Cited by 8
Drug Discovery Study Aimed at a Functional Cure for HBV
Watanabe, T., Hayashi, S., & Tanaka, Y. (2022) · Viruses · doi:10.3390/v14071393 · Cited by 16
Prediction of spontaneous HBeAg seroconversion in HBeAg‐positive chronic hepatitis B patients during the immune clearance phase
Song, G., Rao, H., Feng, B., & Wei, L. (2014) · Journal of Medical Virology · doi:10.1002/jmv.24032 · Cited by 15
Genetic polymorphisms of interleukin‐1‐beta in association with sustained response to anti‐viral treatment in chronic hepatitis B in Chinese
Chan, H. L., Tse, A. M. L., Zhang, M., Wong, V. W., Chim, A. M.-L., Hui, A., & Sung, J. J. �. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02948.x · Cited by 15
Advances in the diagnosis and treatment of hepatitis B
Alazawi, W., & Foster, G. R. (2008) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32830fb924 · Cited by 14
Quantitative Hepatitis B Surface Antigen Titres in Chinese Chronic Hepatitis B Patients over 4 Years of Entecavir Treatment
Chen, E., Wang, T., Bai, L., Tao, C., Liang, T., Liu, C., Liao, J., & Tang, H. (2013) · Antiviral Therapy · doi:10.3851/imp2579 · Cited by 14
The relationship between HBcrAg and HBV reinfection in HBV related post-liver transplantation patients
Urabe, A., Imamura, M., Tsuge, M., Kan, H., Fujino, H., Fukuhara, T., Masaki, K., Kobayashi, T., Ono, A., Nakahara, T., et al. (2016) · Journal of Gastroenterology · doi:10.1007/s00535-016-1240-y · Cited by 14
Treatment of patients with chronic hepatitis B who have failed previous antiviral treatment with pegylated interferon alpha2a (40 kda; PEGASYS).
Chan, H. L., Wong, V. W., Chim, A. M.-L., Wong, G. L., Chan, H., & Sung, J. J. �. (2008) · PubMed · Cited by 14
DNA Repair Factor Poly(ADP-Ribose) Polymerase 1 Is a Proviral Factor in Hepatitis B Virus Covalently Closed Circular DNA Formation
Chen, Y., Yao, Y., Zhao, K., Liu, C., Yuan, Y., Sun, H., Huang, D. F., Zheng, Y., Zhou, Y., Chen, J., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00585-22 · Cited by 13
Artificial recombinant cell-penetrating peptides interfere with envelopment of hepatitis B virus nucleocapsid and viral production
Pan, X., Wei, L., Han, J., Ma, H., Deng, K., & Xu, C. (2010) · Antiviral Research · doi:10.1016/j.antiviral.2010.12.001 · Cited by 13
Les techniques virologiques de diagnostic et de suivi de l’hépatite B
Pawlotsky, J. (2008) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(08)73266-4 · Cited by 13
New developments in HBV molecular diagnostics and quantitative serology
Bowden, D. S., & Thompson, A. J. V. (2008) · Hepatology International · doi:10.1007/s12072-008-9051-8 · Cited by 13
New paradigms in hepatitis B management: only diamonds are forever
Coffin, C. S., & Lee, S. S. (2015) · British Medical Bulletin · doi:10.1093/bmb/ldv039 · Cited by 12
Insights for clinical diagnostic indicators of virus and host in chronic hepatitis B infection
Ou, Q., Guo, J., Zeng, Y., & Chen, H. (2020) · Journal of Viral Hepatitis · doi:10.1111/jvh.13260 · Cited by 12
Increased intrahepatic quasispecies heterogeneity correlates with off-treatment sustained response to nucleos(t)ide analogues in e antigen-positive chronic hepatitis B patients
Chen, L., Gan, Q., Zhang, D. Q., Yao, L., Lin, R., Li, Q., Lin, H.-T., Yu, D., Zhang, X. X., & Pan, C. (2015) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2015.10.007 · Cited by 12
How to achieve immune control in chronic hepatitis B?
van Campenhout, M. J. H., & Janssen, H. L. A. (2014) · Hepatology International · doi:10.1007/s12072-014-9571-3 · Cited by 12
Flowcytometric quantitation of hepatitis B viral antigens in hepatocytes from regular and fine-needle biopsies
van der Laan, L. J. W., Taimr, P., Kok, A., Sprengers, D., Zondervan, P. E., Tilanus, H. W., & Janssen, H. L. A. (2007) · Journal of Virological Methods · doi:10.1016/j.jviromet.2007.01.027 · Cited by 12
Role of hepatitis B antibody in predicting reactivation of resolved hepatitis B virus infection in leukemia patients
Wu, T., Wu, N., Ma, Y., Wu, J. Q., Gao, Y., & Pan, X. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104765 · Cited by 12
Treatment of Patients with Chronic Hepatitis B who have Failed Previous Antiviral Treatment with Pegylated Interferon α2a (40 kDa; PEGASYS®)
Chan, H. L., Wong, V. W., Chim, A. M.-L., Wong, G. L., Chan, H., & Sung, J. J. �. (2008) · Antiviral Therapy · doi:10.1177/135965350801300406 · Cited by 12
A novel hepatitis B virus capsid assembly modulator QL-007 inhibits HBV replication and infection through altering capsid assembly
Xi, J., Gu, Z., Sun, C., Chen, Z., Zhang, T., Chen, R., Liu, T., Liao, H., Zou, J., Wang, J., et al. (2023) · Antiviral Research · doi:10.1016/j.antiviral.2023.105715 · Cited by 11
A review of telbivudine for the management of chronic hepatitis B virus infection
Lui, Y. Y.-N., & Chan, H. L. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.10.1351 · Cited by 11
Besifovir therapy improves hepatic histology and reduces covalently closed circular DNA in chronic hepatitis B patients
Yim, H. J., Kim, W. K., Ahn, S. H., Jung, Y. K., Um, S. H., Sohn, J. H., Jang, J. Y., Kim, D. J., Park, E., Jin, S., et al. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15710 · Cited by 10
Virological Treatment Monitoring for Chronic Hepatitis B
Loggi, E., Gitto, S., Gabrielli, F., Franchi, E., Seferi, H., Cursaro, C., & Andreoné, P. (2022) · Viruses · doi:10.3390/v14071376 · Cited by 9
Association of on‐treatment serum hepatitis B surface antigen level with sustained virological response to nucleos(t)ide analog in patients with hepatitis B e‐antigen positive chronic hepatitis B
Kim, S. S., Lee, D., Lee, M.-H., Cheong, J. Y., & Cho, S. W. (2012) · Hepatology Research · doi:10.1111/j.1872-034x.2012.01065.x · Cited by 9
Treatment of hepatitis B: the next five years
Heathcote, E. J. (2007) · Clinical Medicine · doi:10.7861/clinmedicine.7-5-472 · Cited by 9
Response predictors to treatment with pegylated interferon in chronic hepatitis B
Ferreira, P. R. A., & Tenore, S. D. B. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(10)70104-5 · Cited by 8
Management of chronic hepatitis B: an update
Negro, F. (2011) · Swiss Medical Weekly · doi:10.4414/smw.2011.13264 · Cited by 8
Predictive value of intrahepatic hepatitis B virus covalently closed circular DNA and total DNA in patients with acute hepatitis B and patients with chronic hepatitis B receiving anti-viral treatment
Ruan, P., Zhou, B., Dai, X., Sun, Z.-Q., Guo, X., Huang, J., & Gong, Z. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.1972 · Cited by 8
Loss of intrahepatic HB s A g expression predicts sustained response to peginterferon and is reflected by pronounced serum HB s A g decline
Arends, P., Rijckborst, V., Zondervan, P. E., Buster, E. H. C. J., Çakaloğlu, Y., Ferenci, P., Tabak, F., Akarca, U. S., Simon, K. A., Sonneveld, M. J., et al. (2014) · Journal of Viral Hepatitis · doi:10.1111/jvh.12218 · Cited by 8
Improved Efficacy of a Pegylated Interferon-α-2a Stepwise Optimization Treatment Strategy in the Treatment of Hepatitis B e Antigen-positive Chronic Hepatitis B Patients
Zhou, P., Yang, F., Wang, J., Mao, R., Qi, X., Huang, Y., & Zhang, J. (2015) · Medicine · doi:10.1097/md.0000000000000730 · Cited by 8
Validation of a Sensitive and Specific Real-Time PCR for Detection and Quantitation of Hepatitis B Virus Covalently Closed Circular DNA in Plasma of Chronic Hepatitis B Patients
Takkenberg, R. B., Menting, S., & Beld, M. (2012) · Methods in molecular biology · doi:10.1007/978-1-61779-937-2_7 · Cited by 7
Epigenetic reprogramming promotes the antiviral action of IFNα in HBV-infected cells
Gailhouste, L., Sudoh, M., Qin, X., Watashi, K., Wakita, T., Ochiya, T., Matsuura, T., Kojima, S., & Furutani, Y. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00515-y · Cited by 7
End points of therapy in chronic hepatitis B
Ahmed, S. N. S., Ecochard, M., & Zoulim, F. (2010) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.09.65 · Cited by 7
HBV pregenome RNA as a predictor of spontanous HBeAg seroconversion in HBeAg-positive chronic hepatitis B patients
Song, G., Yang, R., Jin, Q., Liu, J., Rao, H., Feng, B., & Xie, Y. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-03023-8 · Cited by 6
SARS-CoV-2 and chronic hepatitis B: Focusing on the possible consequences of co-infection
Shoraka, S., Mohebbi, S. R., Hosseini, S. M., Ghaemi, A., & Zali, M. R. (2023) · Journal of Clinical Virology Plus · doi:10.1016/j.jcvp.2023.100167 · Cited by 6
RETRACTED: Anti-HBc–positive/HBsAg-negative liver donors pose a higher risk of occult HBV infection but do not cause severe histological damage in liver grafts
Niu, Y., Chen, X., Feng, L., You, H., Ren, X., Liu, H., Zheng, J., Shen, Z., & Jia, J. (2014) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2014.03.016 · Cited by 6
Retracted
Elevated expression of serum soluble ST2 in clinical relapse after stopping long-term Nucleos(t)ide analogue therapy for chronic hepatitis B
Xie, L., Liao, G., Chen, H., Xia, M., Huang, X., Fan, R., Peng, J., Zhang, X., & Liu, H. (2019) · BMC Infectious Diseases · doi:10.1186/s12879-019-4261-3 · Cited by 6
Hepatitis B Virus Genetic Diversity: Disease Pathogenesis
Jayalakshmi, M., Kalyanaraman, N., & Pitchapp, R. (2013) · InTech eBooks · doi:10.5772/53818 · Cited by 6
Serum HBV RNA as a possible marker of HBV replication in the liver during nucleot(s)ide analogue therapy
Kurosaki, M., Tsuchiya, K., Nakanishi, H., Itakura, J., & Izumi, N. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0800-7 · Cited by 6
Prediction of cccDNA dynamics in hepatitis B patients by a combination of serum surrogate markers
Kim, K. S., Iwamoto, M., Kitagawa, K., Park, H., Hayashi, S., Tsukuda, S., Matsui, T., Atsukawa, M., Matsuura, K., Chuaypen, N., et al. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012615 · Cited by 5
Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19
Sagnelli, C., Sica, A., Creta, M., Borsetti, A., Ciccozzi, M., & Sagnelli, E. (2022) · Pathogens · doi:10.3390/pathogens11050567 · Cited by 5
Activity of antiretroviral drugs in human infections by opportunistic agents
Demarchi, I. G., Cardozo, D. M., Aristides, S. M. A., Moliterno, R. A., Silveira, T. G. V., Cardoso, R. F., Bertolini, D. A., Svidzinski, T. I. E., Teixeira, J. J. V., & Lonardoni, M. V. C. (2012) · Brazilian Journal of Pharmaceutical Sciences · doi:10.1590/s1984-82502012000100019 · Cited by 5
Hepatitis B virus DNA quantification with the three-in-one (3io) method allows accurate single-step differentiation of total HBV DNA and cccDNA in biopsy-size liver samples
Taranta, A., Sỹ, B. T., Zacher, B. J., Rogalska, M., Manns, M. P., Bock, C. –., & Wursthorn, K. (2014) · Journal of Clinical Virology · doi:10.1016/j.jcv.2014.04.015 · Cited by 5
Letter: serum HB crAg is a useful marker for disease monitoring, predicting treatment response and disease outcome of chronic hepatitis B virus infection
Wang, M. ‐., Chen, E., Tao, C., & Tang, H. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14673 · Cited by 5
Efficacy and in vitro pharmacological assessment of novel N -hydroxypyridinediones as hepatitis B virus ribonuclease H inhibitors
Woodson, M. E., Walden, H. F., Mottaleb, M. A., Makri, M., Prifti, G., Moianos, D., Pardali, V., Zoidis, G., & Tavis, J. E. (2024) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01455-24 · Cited by 4
A Lower PBMC Estrogen Receptor α Gene Expression in Chronic Hepatitis B Is Associated with a Sustained Virological Response to Pegylated Interferon
Zhang, T., Zhang, Z., Zhang, Y., Ye, J., & Li, X. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0223 · Cited by 4
Clinical utility of hepatitis B surface antigen levels during the natural history and treatment of chronic hepatitis B infection
Çelık, M., Arabul, M., Çekiç, C., Vatansever, S., İpek, S., Aslan, F., & Ünsal, B. (2014) · Gastroenterology Review · doi:10.5114/pg.2014.43758 · Cited by 4
Current practice and contrasting views on discontinuation of nucleos(t)ide analog therapy in chronic hepatitis B
Hadziyannis, E. S., & Hadziyannis, S. J. (2020) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2020.1738219 · Cited by 4
Simple and Reliable Method to Quantify the Hepatitis B Viral Load and Replicative Capacity in Liver Tissue and Blood Leukocytes
Minosse, C., Coen, S., Comandini, U. V., Lionetti, R., Montalbano, M., Cerilli, S., Vincenti, D., Baiocchini, A., Capobianchi, M. R., & Menzo, S. (2016) · Hepatitis Monthly · doi:10.5812/hepatmon.28751 · Cited by 4
Significance of T-Cell Subsets for Clinical Response to Peginterferon Alfa-2a Therapy in HBeAg-Positive Chronic Hepatitis B Patients
Zhu, L., Li, J., Xu, J., Chen, F., Wu, X., & Zhu, C. (2022) · International Journal of General Medicine · doi:10.2147/ijgm.s356696 · Cited by 3
The Significance of Enzyme Immunoassay for the Assessment of Hepatitis B Virus Core-Related Antigen following Liver Transplantation
Fujimoto, M., Ichikawa, T., Nakao, K., Miyaaki, H., Shibata, H., Eguchi, S., Takatsuki, M., Nagaoka, S., Yatsuhashi, H., Kanematsu, T., et al. (2009) · Internal Medicine · doi:10.2169/internalmedicine.48.2000 · Cited by 3
Hepatitis B Virus Drug Resistance: Mechanism and Clinical Implications for the Prevention of Treatment Failure
Zoulim, F., & Lucifora, J. (2006) · Future Virology · doi:10.2217/17460794.1.3.361 · Cited by 3
Hepatitis B
Chan, H. L., & Wong, V. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-0881-3.00030-9 · Cited by 3
Unraveling the Complexities of Hepatitis B Virus Control: A Mathematical Modeling Approach
Ibrahim, M. M., Byun, J. H., Mannan, M. M. N., Jung, I. H., & Kim, K. S. (2025) · Journal of Mathematics · doi:10.1155/jom/6616833 · Cited by 2
Consequences of Persistent HBV infection in HIV: the Double-Edged Sword of Nucleos(t)ide Analogs
Boyd, A. C., Girard, P., & Lacombe, K. (2012) · Future Virology · doi:10.2217/fvl.11.144 · Cited by 2
Antiviral Therapy for Chronic Hepatitis B
(2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-11-200712040-00184 · Cited by 2
Navigating the landscape of hepatitis B virus reactivation in HBsAg-positive and HBsAg-negative resolved infections: Current insights and future directions
Lambuk, L., Noor, A. A. M., Lambuk, F., Kub, T. N. T., Sadikan, M. Z., Yusop, N., Mohamud, R., & Hashim, N. H. H. N. (2025) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2025.10.012 · Cited by 1
Oral Antiviral Therapy for Chronic Hepatitis B Virus Infection: Is Continuous Treatment Needed?
Lee, C. H. (2014) · Gastroenterology & Hepatology Open Access · doi:10.15406/ghoa.2014.01.00005 · Cited by 1
Antiviral therapy for chronic hepatitis B: are we doing any good to patients?
Wong, V. W., & Sung, J. J. �. (2009) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkp189 · Cited by 1
Hepatitis B viral infection of hepatic progenitor cells. Resolving unresolved questions?
Minuk, G. Y., & Baruch, Y. (2016) · Medical Hypotheses · doi:10.1016/j.mehy.2016.04.011 · Cited by 1
Quantification de l’AgHBs : nouvel outil virologique pour la prise en charge de l’hépatite B chronique
Maylin, S. (2012) · Revue Francophone des Laboratoires · doi:10.1016/s1773-035x(12)71777-x · Cited by 1
Regulation Mechanism of HBV cccDNA
Cheng, J., Quan, M., Li, M., Liu, S., & Wang, Q. (2012) · Infection International/Infection International (Electronic Edition) · doi:10.1515/ii-2017-0010 · Cited by 1
Marcadores virológicos en la infección por VHB
Rodríguez‐Frias, F., & Jardí, R. (2006) · Gastroenterología y Hepatología · doi:10.1157/13097570 · Cited by 1
The Clinical Virology of Hepatitis B
Revill, P. A., & LOCARNINI, S. A. (2006) · Future Virology · doi:10.2217/17460794.1.3.349 · Cited by 1
Entwicklungen in der Hepatitis-B-Diagnostik: Quantitatives HBsAg, HBV-Genotypen, Real-Time PCR HBV-DNA
Popow‐Kraupp, T., & Straßl, R. P. (2012) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Controversies Regarding the Hepatitis B Immune Globulin Prophylaxis (HBIG) for Liver Transplantation Recipients
Jazayeri, S. M., Rizzetto, M., & Alavian, S. M. (2014) · Journal of Gastroenterology and Hepatology Research · doi:10.17554/j.issn.2224-3992.2014.03.428
Optimizing Treatment Strategies Using Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B
Reijnders, J. G. P. (2010) · RePub (Erasmus University Rotterdam)
Host and Viral Predictors of Response to Antiviral Therapy in Chronic Hepatitis B
Sonneveld, M. J. (2013) · EUR Research Repository (Erasmus University Rotterdam)
Comparison of Hepatitis B Virus DNA, RNA, and Core Related Antigen as Predictors of Lamivudine Resistance in Patients with Chronic Hepatitis B
Matsumoto, A., Maki, N., Yoshizawa, K., Umemura, T., Joshita, S., & Tanaka, E. (2010) · SOAR (Shinshu University) · doi:10.11441/shinshumedj.58.153

Authors: Sung, J. J. Y., Wong, M.-L., Bowden, S., Liew, C.-T., Hui, A. Y., Wong, V. W. S., Leung, N. W. Y., Locarnini, S., & Chan, H. L. Y.
Affiliations: Chinese University of Hong Kong (HK)
Victorian Infectious Diseases Reference Laboratory (AU)
Alice Ho Miu Ling Nethersole Hospital (CN)
Corresponding author: Sung, Joseph J.Y.
ORCID: Sung, Joseph J.Y.
Hui, Alex Y.
Wong, Vincent W.S.
Locarnini, Stephen
Chan, Henry L.Y.
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2005-06
Volume: 128
Issue: 7
Pages: 1890-1897
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1053/j.gastro.2005.03.009
OpenAlex: W1992475294
Cited by: 218
References: 32
Citations by year: 2026: 1 · 2025: 4 · 2024: 1 · 2023: 3 · 2022: 8 · 2021: 4 · 2020: 7 · 2019: 7 · 2018: 3 · 2017: 10 · 2016: 12 · 2015: 12 · 2014: 16 · 2013: 14 · 2012: 12
FWCI: 12.43
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Funders: Chinese University of Hong Kong
Topics: Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Health Sciences › Medicine › Hepatology › Hepatitis C virus research
Health Sciences › Medicine › Hepatology › Liver physiology and pathology
Keywords: hepatitis B virus, covalently closed circular DNA, chronic hepatitis B, sustained virological response, lamivudine, pegylated interferon, HBeAg-positive, prognostic factors, serum HBV DNA
MeSH terms: Interferon alpha-2, Adult, Antiviral Agents, DNA, Circular, DNA, Viral, Drug Therapy, Combination, Female, Hepatitis B virus, Humans, Liver, Male, Polyethylene Glycols, Predictive Value of Tests, Recombinant Proteins, Sensitivity and Specificity, Polymerase Chain Reaction, Treatment Outcome, Interferon-alpha, Lamivudine, Hepatitis B, Chronic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intrahepatic Hepatitis B Virus Covalently Closed Circular DNA Can Be a Predictor of Sustained Response to Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks